XML 39 R20.htm IDEA: XBRL DOCUMENT
v3.21.1

Product Sales (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Revenues [Abstract] |
Schedule of product sales | Net product sales consist of the following:
(In millions) |  | Three Months Ended March 31,
Net Product Sales in the United States |  | 2021 |  | 2020
EYLEA® |  | $ | 1,347.0 |  |  | $ | 1,172.0 |
Libtayo® |  | 69.1 |  |  | 61.7 |
Praluent® |  | 43.3 |  |  | *
REGEN-COV™ (casirivimab with imdevimab) |  | 262.2 |  |  | — |
Evkeeza™ |  | 0.5 |  |  | — |
ARCALYST® |  | 2.2 |  |  | 3.0 |
|  | $ | 1,724.3 |  |  | $ | 1,236.7 |
* Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.
Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:
|  | Statement of Operations Classification |  | Three Months Ended March 31,
(In millions) |  |  | 2021 |  | 2020
Antibody: |  |  |  |  |  |
Regeneron's share of profits in connection with commercialization of antibodies |  | Collaboration revenue |  | $ | 260.6 |  |  | $ | 170.9 |
Reimbursement for manufacturing of commercial supplies |  | Collaboration revenue |  | $ | 105.6 |  |  | $ | 80.1 |
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 30.1 |  |  | $ | 77.6 |
Regeneron's obligation for its share of Sanofi research and development expenses |  | Research and development expense |  | $ | (11.9) |  |  | $ | (16.7) |
Reimbursement of commercialization-related expenses |  | Reduction of Selling, general, and administrative expense |  | $ | 60.4 |  |  | $ | 91.2 |
Immuno-oncology: |  |  |  |  |  |
Regeneron's share of losses in connection with commercialization of Libtayo outside the United States |  | Collaboration revenue |  | $ | (6.1) |  |  | $ | (6.2) |
Reimbursement for manufacturing of commercial supplies |  | Collaboration revenue |  | $ | 4.7 |  |  | $ | 2.1 |
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 21.9 |  |  | $ | 39.9 |
Reimbursement of commercialization-related expenses |  | Reduction of Selling, general, and administrative expense |  | $ | 18.5 |  |  | $ | 10.4 |
Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits |  | Cost of goods sold |  | $ | (30.4) |  |  | $ | (26.8) |
Amounts recognized in connection with up-front payments received |  | Other operating income |  | $ | 22.9 |  |  | $ | 16.5 |
Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:
|  | Statement of Operations Classification |  | Three Months Ended March 31,
(In millions) |  |  | 2021 |  | 2020
Regeneron's net profit in connection with commercialization of EYLEA outside the United States |  | Collaboration revenue |  | $ | 308.9 |  |  | $ | 253.8 |
Reimbursement for manufacturing of commercial supplies |  | Collaboration revenue |  | $ | 13.9 |  |  | $ | 27.6 |
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 10.8 |  |  | $ | 12.0 |
Regeneron's obligation for its share of Bayer research and development expenses |  | Research and development expense |  | $ | (12.5) |  |  | $ | (8.1) |
Amounts recognized in our Statements of Operations in connection with our collaboration with Teva are as follows:
|  | Statement of Operations Classification |  | Three Months Ended March 31,
(In millions) |  |  | 2021 |  | 2020
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 19.8 |  |  | $ | 25.2 |
Amounts recognized in connection with up-front and development milestone payments received |  | Other operating income |  | $ | 12.2 |  |  | $ | 16.6 |
Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:
|  | Statement of Operations Classification |  | Three Months Ended March 31,
(In millions) |  |  | 2021 |  | 2020
Regeneron's share of gross profits in connection with sales of casirivimab with imdevimab |  | Collaboration revenue |  | $ | 66.8 |  |  | — |
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 86.8 |  |  | — |
Schedules of Concentration of Risk, by Risk Factor | Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
|  | Three Months Ended March 31,
|  | 2021 |  | 2020
Besse Medical, a subsidiary of AmerisourceBergen Corporation |  | 46 | % |  | 54 | %
McKesson Corporation |  | 29 | % |  | 36 | %
U.S. Government (see Note 3) |  | 13 | % |  | — |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration